1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Commercial Potential of the Forthcoming US Biosimilars Market 

  • February 2014
  • 156 pages
  • Frost & Sullivan
Report ID: 2042879

Summary

Table of Contents

An Addendum to “Specialty Physicians Discuss their Opinions of the United States Biosimilars Market”

Executive Summary

•The arrival of biosimilars, or highly similar copies of biopharmaceutical products, to the US market is imminent. Although the products have been available elsewhere—including Europe—for several years, physicians and other key stakeholders in the United States have only recently begun to anticipate their arrival.
•This panel discussion was conducted to preview the thoughts and expectations of specialty physicians who would be expected to be among the first customers of biosimilars, with the objective of gaining insight into some of the major factors that could influence market uptake.
•Based on this representative sample of physicians, the overall adoption of biosimilars can be expected to experience a widespread uptake due to anticipated access to comparable therapeutic options at a lower cost versus high-cost biologics. Main factors with the potential to influence the rate and extent of uptake include cost, safety and efficacy data including testing in specific patient populations, and reputation of the manufacturer.
•Potential skepticism may be overcome with the help of convincing noninferiority clinical data for products from reputable companies that are highly experienced with biologics. Educational programs deemed to be unbiased that convey this data could help increase awareness and boost physician confidence in biosimilar products.

Objective

Frost & Sullivan assessed physicians’ willingness to prescribe biosimilars in the United States.
The objective of this research was to conduct a highly qualitative analysis of a representative sample of practicing specialty physicians in the United States in the spirit of an interactive roundtable discussion.
The primary goal was to encourage participants to freely express their opinions and ideas around all aspects of a topic, facilitating a free exchange about how biosimilars will impact their practice and the overall US healthcare market.
This research was not intended to produce quantitative data.

Methodology

The biosimilar research panel consisted of preselected participants and was conducted via online moderated discussion boards over a three-day period (October 11-13, 2011). A series of questions was asked on current topics of interest to specialty physicians as well as pharmaceutical and biotechnology companies. Questions and discussions were designed to gauge both short-term and long-term trends and impacts.

Participants

The panel consisted of specialty physicians: seven oncologists, seven rheumatologists, and 6 hematologists. Panel participants were randomly selected from a pool of prescreened, qualified candidates and mainly represented hospitals and independent practices across the United States. Selection of specialty practices was based on the therapy area of those biosimilar agents anticipated to enter the US market in the foreseeable future.

Biopharmaceuticals and Biosimilars

•Biopharmaceuticals represent one of the most important innovations in medical history. However, these breakthrough therapies are extremely costly, owing to the magnitude of investment necessary in their discovery and development, driving a need for less-costly alternatives.
•While current regulations allow for the approval of generic copies of conventional pharmaceuticals at greatly reduced costs, until recently there has not been the technology nor regulatory pathway with which to introduce lower-cost versions of biologics.
•The US Congress has recently enacted legislation to enable and encourage the introduction of biosimilars/follow-on biologics, paving the way into an untapped market.
•However, many obstacles to a clear abbreviated regulatory pathway and market uptake in the US remain, such as guidance regarding clinical research requirements, naming convention, and end-user acceptance to name a few.
•While sponsors await final guidance from the Food and Drug Administration (FDA), Eli Lilly, and Boehringer Ingelheim have opted to file LY2963016, a biosimilar version of Sanofi’s Lantus (insulin glargine) through the 505(b)(2) pathway, and the application was recently accepted by the FDA in December 2013.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017
  • by MP Advisors

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.